Last month we set ourselves the “10 Laps 10km” challenge for Childhood Cancer Awareness.
Now we have closed the GoFundMe and counted the charity buckets. We are delighted to announce we raised a grand total of €1419! We are over the moon with this sum, as 2020 required a very different kind of fundraiser than previous years.
Our three chosen charities: Children’s Health Foundation Crumlin (formerly CMRF), the Conor Foley Neuroblastoma Cancer Research Foundation, and Neuroblastoma UK, will each receive just over €470.
We’d like to say big thank you to everyone who donated. It will make a huge difference for these charities, this year especially, paving the way to better treatment options for children with cancer in the future.
This year our research team will be taking part in the virtual VHI mini-marathon on the 7th of October 2020 in honour of Childhood Cancer Awareness Month. For every one euro donated to research only 1 cent of this goes to ALL childhood health conditions including cancer. Therefore, the donations we receive will be split equally among some wonderful children’s charities. These charities include: The Conor Foley Neuroblastoma Research Foundation (CFNRF), Neuroblastoma UK (NBUK), Children’s Research & Medical Foundation (CRMF) CrumlinIf you would like to get involved in this amazing virtual event and help us raise vital funds for childhood cancers, attached is a link where you can register to the event: https://www.vhiwomensminimarathon.ie/power-of-10.
Our team is very appreciative of the support we get from these charities. We would be very grateful if you could help support our virtual marathon challenge by making a donation to these wonderful charities in light of childhood cancer awareness month.
Last year we managed to raise an amazing 1750 euro taking part in the 8km Hell and Back challenge. We are eager to surpass that target this year. All donations no matter how small are appreciated: https://www.gofundme.com/f/c7dkeu-childhood-cancer-awarness-month
Today marks the start of Childhood Cancer Awareness Month.
I like this photo of a lovely fountain capturing 3 girls under umbrellas (Drei-Mädchen-Brunnen) in Ballplatz Mainz. It is about a happy childhood; every child deserves a happy childhood. So, I select it again to support #ChildhoodCancerAwarnessMonth.
Childhood cancer is an umbrella term for many other types of this disease. This month is a big channel to support and learn more about kids with cancer, their loving families, the doctors and caregivers who looking after them and treating them, the young survivors of cancer and those kids and teens who lost their battle, and the scientists who working hard to find a way to stop childhood cancer.
When it comes to a disease, we have to acknowledge that children are not little adults. They are constantly developing. So their diseases have a different way to progress and respond to treatment. This is very true for childhood cancers. For example, children diagnosed with neuroblastoma before a 1.5 years old mark will do better than older children.
Every 100th cancer patient is a child. Cancer is the 2nd most common cause of death among children after accidents. The most common types of childhood cancer are:
Leukaemia and lymphoma (blood cancers)
Brain and other central nervous system tumours
Muscle cancer (rhabdomyosarcoma)
Kidney cancer (Wilms tumour)
Neuroblastoma (tumour of the non-central nervous system)
Bone cancer (osteosarcoma)
Testicular and ovarian tumours (gonadal germ cell tumours)
As a scientist myself, I know that behind many current default living settings is intensive research in the past. IT would have never advanced if at some stage no discoveries in physics, chemistry have happened. We would have never been able to fight bacteria infection of no antibiotic was discovered. What about discovering of insulin? This list can go on and on… Just imagine if no research happens now. How we could cope with the current coronavirus pandemic? How we could help many people with cancer to have a healthier and longer life?
Breakthrough Cancer Research united many sports professionals and enthusiasts to build up a spirited community to support vital cancer research during the COVID-19 restrictions. I heard about this race by chance – my PhD student signed up to do it. When I read it, I thought it sounds achievable to complete 20K within a month. One small step at a time. It was a slow process. But it has transformed me.
At the finish line, I became addicted to my steady jogging within the allowed 2K distance every day. I have to confess that it is incredibly challenging for me to wake up, tie my sport shoelaces and go for a jog. My body wants a smooth transition from sleep to the active state, particularly when you are at home every day! This was normality in the past.
What did I discover going through this transformation? My body knows better its needs. Every morning I start it slowly with just an intensive walk. In 2-3 minutes, my body requests more fresh air in my lungs and higher endorphin levels in my blood. I can’t resist and start jogging. 🙂
Why mornings one may ask? I have tried different times during the day. My body has decided on morning hours even it is challenging… No option to negotiate.
It was the end of July when Ciara suggested doing ‘Hell and Back‘ for Childhood Cancer Awareness Month. It sounded challenging and new for me so I supported this idea. We branded ourselves as #Lysis2Kill connecting to our biological background and crafted our very own T-shirts.
I was glad that I did not search for much about this challenge… I hoped that my current fitness level would suffice to complete it. Maybe coming even in the last wave…
It was on sunny Sunday. The day was fantastic. A few clouds in the sky. Many people came and did similar stuff – fundraising for the charity of their choice. Some did it for their own satisfaction or just for fun.
The atmosphere was buzzing. Throughout the challenge, people helped others they didn’t even know. Everyone cheered and smiled back. The team spirit was just fantastic.
We ran, crawled, climbed, walked & swam. There were moments when I prompted myself to think only about great and picturesque surroundings. We ended up battered and bruised. It was tough and our bodies were recovering for a good while after… However, saying that I loved every minute of it. It was an exceptional experience.
#Lysis2Kill completed the Hell&Back challenge dedicated to raising awareness to Childhood Cancer and Childhood Cancer Research Charities that work hard and dream big. Some of them are established and run by parents who lost their child to neuroblastoma. Thanks to our supporters, we raised 1.7K to support three wonderful charities.
We put together these funds and the Waffle Baking Morning money which gave as final 2.1K Euros. We equally divided the pot between Children’s Medical Research Foundation, Neuroblastoma UK and the Conor Foley Neuroblastoma Cancer Research Foundation.
Now, when my team has expanded, it is so easy to come up with fundraising ideas and then develop one in a well-rounded event. In February, we ran Hot Chocolate Morning to raise awareness in childhood cancer and celebrate the International Childhood Cancer Awareness Day. We have an entire month of September to make this disease visible. It was the first time for some of my team members.
“Last Friday, I got to take part in my first fundraising event at the Royal College of Surgeons in Ireland. Our team hosted a waffle morning for #childhoodcancerawarenessmonth and we are delighted to have raised €403.85 thanks to everyone’s generous donations! Our fundraising does not stop here, in just a few weeks time all 7 of us will be taking on the 8km Hell and Back challenge to raise more awareness and funds for our four chosen charities: CMRF Crumlin, Neuroblastoma UK, and the Conor Foley Neuroblastoma Cancer Research Foundation. We hope everyone enjoyed their little Friday treat!” Catherine Murphy, PhD student funded by Neuroblastoma UK
I have started a new chapter in my research career by joining the Department of Anatomy and Regenerative Medicine as a StAR Research Lecturer. By a coincidence, it has happened on the first day of Childhood Cancer Awareness Month. It might be symbolic.
The new start requires fresh ideas. Now, the new chapter is called Cancer Bioengineering Group. Exciting times ahead!
This Friday the 13th of September the Cancer-Bioengineering research group will be hosting a ‘Waffle Morning’ in honour of Childhood Cancer Awareness Month.
Pop into the ground floor staff common room from 8.30am to enjoy some delicious freshly made waffles and support the wonderful charities; CMRF Crumlin, NCRC, CFNCRF and NBUK.
We promise to bake 3D waffle engineered scaffolds and populate them with marshmallows, berries, cream and Nutella!
Exciting times ahead for my team – to study neuroblastoma – immune cells interaction. This 3 years project is funded by Neuroblastoma UK to support the interdisciplinary collaboration between experts in fields of neuroblastoma biology, immunology and tissue engineering from Royal College of Surgeons in Ireland, Trinity College Dublin and Queen Mary University London.
Catherine will grow different neuroblastoma cells together with immune cells using a 3D printing technology. She will travel to Queen Mary University London and learn how to do 3D tumour bioprinting. This technology allows the generation of reproducible scaffolds that replicate the architecture of tumour tissues as seen in patients. She will use RCSI/AMBER facilities to optimise this model here and to study how immune cells recognise cancer cells, attack and eventually kill them. This experimental model will help us to advance current immunotherapies and develop more effective treatments for neuroblastoma.
I had one of the most enjoyable poster sessions in the last few years! A genuine interest in our 3D in vitro cancer models by both academics and Industry. Hope, to keep the ball rolling and strengthen these new links.
The Symposium programme was an excellent balance of the new transnational outcomes with hardcore developmental cellular programmes. From ‘How neuronal precursors select their fate and how they can escape the developmental constraints? How this knowledge can help to advance our understanding of neuroblastoma aetiology?’ to ‘New drugs that demonstrated great potency in pre-clinical studies’ via ‘how we can work together more efficiently to progress quicker’
Indeed, the success of the research meeting became possible thanks to the strategic vision and leadership of organisers!
Cancer Research UK Cambridge Centre Neuro-oncology Programme Session
Chair: Kate Wheeler (Oxford Children’s Hospital)
13:10 – 13:40 Sandra Ackermann (Cologne): The genetic basis of favourable outcome and fatal tumour progression in neuroblastoma
13:40 – 14:10 Rogier Versteeg (Amsterdam): The dark side of neuroblastoma
14:10 – 14:40 Katleen de Preter (Ghent): Improved diagnosis and risk stratification of paediatric cancers using liquid biopsies
14:40 – 14:55 Sue Burchill (Leeds): Self-renewing neuroblastoma cells isolated from bone marrow aspirates of children with stage M disease share a mesenchymal expression signature: an NCRI CCL CSG Neuroblastoma Group Study
14:55 – 15:15 Combined discussion
15:15 – 15:45 Tea with Posters
Session 2: Targeted & combination therapy I
Cancer Research UK Cambridge Centre Neuro-oncology Programme Session
Chair: Marie Arsenian Henriksson (Karolinska)
15:45 – 16:15 Frank Westermann (Heidelberg): Novel metabolic dependencies of MYCN-driven neuroblastoma
16:15 – 16:45 Gerard Evan (Cambridge): Is Myc really master of the universe?
16:45 – 17:00 Melinda Halasz (University College Dublin): Anti-Cancer Effects of Diphenyleneiodonium Chloride (DPI) In MYCN-Amplified Neuroblastoma
17:00 – 17:15 Evon Poon (ICR, Sutton): Pharmacological blockade of high-risk MYCN driven neuroblastoma using an orally-bioavailable CDK2/9 inhibitor
17:15 – 17:35 Combined discussion
Downing College – Main Hall.jpg
17:35 – 19:15 Poster viewing & Drinks
19:30 Symposium Dinner at Downing College (map for dinner)
FRIDAY 12TH APRIL 08:30 – 08:50 Coffee & pastries
Session 3: Neural crest & differentiation therapy I
Chair: Margareta Wilhelm (Karolinska)
08:50 – 09:20 Igor Adameyko (Karolinska): Normal development of sympathoadrenal system resolved with lineage tracing and single cell transcriptomics
09:20 – 09:50 Quenten Schwarz (Adelaide): Guiding sympathoadrenal neural crest cells to the adrenal primordia
09:50 – 10:05 Claudia Linker (King’s College London): Notch coordinates cell cycle progression and migratory behaviour leading to collective cell migration
10:05 – 10:20 Combined discussion
10:20 – 10:50 Coffee with Posters
Session 4: Neural crest & differentiation therapy II
Chair: Gareth Evans (York)
10:50 – 11:20 Karen Liu (King’s College London): ALK and GSK3 – shared features of neuroblastoma and neural crest
11:20 – 11:35 Anestis Tsakiridis (Sheffield): Efficient generation of trunk neural crest and sympathetic neurons from human pluripotent stem cells via a neuromesodermal progenitor intermediate
11:35 – 12:05 Anna Philpott (Cambridge): Using developmental mechanisms to drive differentiation of neuroblastoma
12:05 – 12:20 Combined discussion
12:20 – 13:20 Lunch with Posters
Session 5: Targeted & combination therapy II
Chair: Bengt Hallberg (Gothenburg)
Cancer Research UK Cambridge Centre Paediatrics Programme Lecture:
13:20 – 13:50 Sharon Diskin (Philadelphia): A multi-omic surfaceome study identifies DLK1 as a candidate oncoprotein and immunotherapeutic target in neuroblastoma
13:50 – 14:05 Donne Nile (Glasgow): Manipulation of cancer cell metabolism for neuroblastoma combination therapy with targeted radiotherapy
14:05 – 14:35 Suzanne Turner (Cambridge): CRISPR-dCas9 screens to identify resistance mechanisms to ALK in neuroblastoma
14:35 – 14:50 Combined discussion
14:50 – 15:20 Tea with Posters
15:20 – 15:30 Poster prizes
Session 6: Targeted & combination therapy III
Chair: John Lunec (Newcastle)
15:30 – 16:00 Per Kogner (Karolinska): The PPM1D encoded WIP1 phosphatase is an oncogene significant for cancer development and tumour progression and a druggable therapy target in neuroblastoma and medulloblastoma. A hint as to how aggressive childhood cancer manages with wild-type p53
16:00 – 16:15 Deb Tweddle (Newcastle): Preclinical assessment of MDM2/p53, ALK and MEK inhibitor combinations in neuroblastoma
16:15 – 16:30 Sally George (ICR, Sutton): A CRISPR-Cas9 genomic editing and compound screening approach identifies therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
16:30 – 16:45 Miriam Rosenberg (Jerusalem): Expression- and immune-profiling of neuroblastoma-associated Opsoclonus Myoclonus Ataxia Syndrome (OMAS) to identify features of auto- and tumour-immunity